Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


1.		ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and older				Pharmaceutical / Industry				D4200C00032 6474IL/0032, NCT00312377


2.		Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				D4200C00057 EUDRACT No. 2006-000259-16, NCT00364351


3.		Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				D4200C00036 EUDRACT No. 2006-003695-35, NCT00418886


4.		Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				06-377 NCT00441142

Last Modified: 5/20/2008 First Published: 11/24/2002


5.		Phase II Study of ZD6474 in Patients With Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				CAN-NCIC-IND145 ZENECA-6474IL/0004, IND145

Last Modified: 9/28/2007 First Published: 1/26/2003


6.		Phase II Randomized Study of ZD6474 and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to Platinum-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0208009 ZENECA-6474IL/0006, NCT00054093

Last Modified: 9/25/2007 First Published: 7/26/2003


7.		Phase II Randomized Study of ZD6474 in Patients With Small Cell Lung Cancer Who Responded to Induction Chemotherapy With or Without Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 16				Other				CAN-NCIC-BR20 ZENECA-6474IL/0005, NCT00066313, BR20

Last Modified: 12/13/2004 First Published: 10/25/2003


8.		Phase II Randomized Study of ZD6474 Versus Gefitinib (ZD1839) in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Who Failed Prior First-Line Platinum-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-03090 ZENECA-6474IL/0003, NCT00059722


9.		Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				D4200C00008 NCT00098345


10.		A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				D4200C00068 NCT00358956

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute